Eli Lilly (LLY) increased its sale of Mounjaro, its weight-loss and diabetes drug, by 60% in India in May from April, Satviki Sanjay of Bloomberg reports. The company sold $1.5M worth of injections last month, Bloomberg said, citing market analysis firm Pharmarack Technologies. “The patient number may have actually doubled” in May from April Pharmarack Vice President Sheetal Sapale told Bloomberg News. The demand is rising gradually and is expected to continue.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Novo Nordisk Stock (NVO) Shakes off Links Between Weight Jabs and Vision Loss
- Study finds GLP-1s may have link to eye disease, STAT reports
- Vaccine opponent hired by RFK Jr. searches CDC record for autism link, WSJ says
- Eli Lilly Stock (LLY) Gets Multiple Wall Street Downgrades
- Salesforce initiated, Dollar Tree upgraded: Wall Street’s top analyst calls